Literature DB >> 22006790

Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.

Carrie A Thompson1, Matthew J Maurer, James R Cerhan, Jerry A Katzmann, Stephen M Ansell, Thomas M Habermann, William R Macon, George J Weiner, Brian K Link, Thomas E Witzig.   

Abstract

The serum free light chain (FLC) assay quantitates free immunoglobulin kappa and lambda light chains, which has prognostic value in plasma cell dyscrasias. However, there is limited data on serum FLC in lymphoid malignancies. We analyzed the association of pretreatment FLC with event-free survival (EFS) and overall survival (OS) in 100 patients with Hodgkin lymphoma (HL). Elevated polyclonal FLC were present in 30% of patients; these patients had an inferior EFS (HR = 4.84; 95% CI: 1.84-12.7) and OS (HR = 8.87; 95% CI: 2.35-33.52) compared to patients with normal FLC. Further studies of FLC in HL are warranted.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22006790      PMCID： PMC3588858          DOI： 10.1002/ajh.22168

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  13 in total

1.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Authors:  A R Bradwell; H D Carr-Smith; G P Mead; L X Tang; P J Showell; M T Drayson; R Drew
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Martha Q Lacy; Jerry A Katzmann; S Vincent Rajkumar; Roshini S Abraham; Suzanne R Hayman; Shaji K Kumar; Raynell Clark; Robert A Kyle; Mark R Litzow; David J Inwards; Stephen M Ansell; Ivana M Micallef; Luis F Porrata; Michelle A Elliott; Patrick B Johnston; Philip R Greipp; Thomas E Witzig; Steven R Zeldenrust; Stephen J Russell; Dennis Gastineau; Morie A Gertz
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

3.  Immunoglobulin free light chains and solitary plasmacytoma of bone.

Authors:  David Dingli; Robert A Kyle; S Vincent Rajkumar; Grzegorz S Nowakowski; Dirk R Larson; John P Bida; Morie A Gertz; Terry M Therneau; L Joseph Melton; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

4.  Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.

Authors:  T Marafioti; M Hummel; H D Foss; H Laumen; P Korbjuhn; I Anagnostopoulos; H Lammert; G Demel; J Theil; T Wirth; H Stein
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

5.  Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

Authors:  Matthew J Maurer; Ivana N M Micallef; James R Cerhan; Jerry A Katzmann; Brian K Link; Joseph P Colgan; Thomas M Habermann; David J Inwards; Svetomir N Markovic; Stephen M Ansell; Luis F Porrata; Patrick B Johnston; Grzegorz S Nowakowski; Carrie A Thompson; Mamta Gupta; Sergei I Syrbu; Paul J Kurtin; William R Macon; Daniel A Nikcevich; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

6.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

7.  Light and immunoelectronmicroscopic study of Hodgkin's disease: evidence of immunoglobulin synthesis by tumor cells.

Authors:  M J Gladkowska-Dura; W T Dura; W W Johnson
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1981

8.  Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.

Authors:  Roshini S Abraham; Jerry A Katzmann; Raynell J Clark; A R Bradwell; Robert A Kyle; Morie A Gertz
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

9.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Authors:  D Hasenclever; V Diehl
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327
View more
  9 in total

1.  Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.

Authors:  Thomas E Witzig; Matthew J Maurer; Mary J Stenson; Cristine Allmer; William Macon; Brian Link; Jerry A Katzmann; Mamta Gupta
Journal:  Am J Hematol       Date:  2014-02-10       Impact factor: 10.047

2.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

3.  Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.

Authors:  Yuki Nakajima; Naoto Tomita; Reina Watanabe; Yasufumi Ishiyama; Eri Yamamoto; Daisuke Ishibashi; Megumi Itabashi; Satoshi Koyama; Hiroyuki Takahashi; Ayumi Numata; Hirotaka Takasaki; Rika Kawasaki; Hideyuki Kuwabara; Masatsugu Tanaka; Chizuko Hashimoto; Katsumichi Fujimaki; Rika Sakai; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Med Oncol       Date:  2014-08-21       Impact factor: 3.064

4.  Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

Authors:  James R Cerhan; Brian K Link; Thomas M Habermann; Matthew J Maurer; Andrew L Feldman; Sergei I Syrbu; Carrie A Thompson; Umar Farooq; Anne J Novak; Susan L Slager; Cristine Allmer; Julianne J Lunde; William R Macon; David J Inwards; Patrick B Johnston; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Neil E Kay; George J Weiner; Thomas E Witzig
Journal:  Int J Epidemiol       Date:  2017-12-01       Impact factor: 7.196

5.  Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Neil E Kay; Timothy G Call; Sara J Achenbach; James R Cerhan; Susan L Slager; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-06-04       Impact factor: 6.998

6.  A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts.

Authors:  Hervé Ghesquières; Beth R Larrabee; Olivier Casasnovas; Matthew J Maurer; James D McKay; Stephen M Ansell; Dorothy Montgomery; Yan W Asmann; Katrina Farrell; Aurélie Verney; Susan L Slager; Cristine Allmer; Aurore Perrot; Richard Delarue; Thomas M Habermann; Jehan Dupuis; Brian K Link; Danielle Canioni; Ahmet Dogan; Wendy Cozen; Ruth F Jarrett; James R Cerhan; Gilles Salles
Journal:  Br J Haematol       Date:  2016-09-09       Impact factor: 6.998

7.  FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.

Authors:  Hervé Ghesquières; Ahmet Dogan; Brian K Link; Matthew J Maurer; Julie M Cunningham; Anne J Novak; Beth R Larrabee; Susan L Slager; Cristine Allmer; Thomas M Habermann; Stephen M Ansell; James R Cerhan
Journal:  Leuk Lymphoma       Date:  2013-06-03

8.  Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.

Authors:  Thomas E Witzig; Matthew J Maurer; Thomas M Habermann; Brian K Link; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Joseph P Colgan; David J Inwards; Luis F Porrata; Svetomir N Markovic; Patrick B Johnston; Yi Lin; Carrie Thompson; Mamta Gupta; Jerry A Katzmann; James R Cerhan
Journal:  Am J Hematol       Date:  2014-09-26       Impact factor: 10.047

9.  CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.

Authors:  Magdy Bedewy; Shereen El-Maghraby; Ahmed Bedewy
Journal:  Blood Res       Date:  2013-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.